BioVaxys Technology Corp. (BVAXF)

0.0628 +0.0062 (+10.91%) At close: 02:47PM EDT

BioVaxys Technology Corp.

146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
646 452 7054
https://biovaxys.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. James Christopher Passin	Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director	91.5k	N/A	1972
Mr. Kenneth E. Kovan	Co-Founder, President & COO	175.74k	N/A	1963
Dr. David Berd M.D.	Co-Founder & Chief Medical Officer	N/A	N/A	1943

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.

Corporate Governance

BioVaxys Technology Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.